Liquid Biopsy Workshop

HUPO2017 Congress Workshop on

Liquid Biopsy: Principles, Process and Practices

Registration Fee – €45

Organising Committee
Sudhir Srivastava, NIH, USA; John Semmes, East Virginia Medical School, USA; John Timms, University College London, UK; Stephen Pennington, University College Dublin, Ireland and Chris Sutton, University of Bradford, UK


In the era of personalized medicine it is highly desirable to have non-invasive or minimally invasive methods to measure molecular features and use them to determine and follow longitudinally the health and disease status of an individual. The molecular data obtained from such methods may also help to obtain a broader molecular understanding of disease. One such approach is through proteomics based ‘liquid biopsies’ that can be used to characterize specific disease status and monitor changes over time using repeat sampling of biofluids. While much current research on liquid biopsies uses blood or derivatives thereof, it is evident that other biofluids can be used including urine, sputum, and saliva and cerebro-spinal fluid. Liquid biopsies have the potential to help healthcare professionals screen for disease, stratify patients for the best treatment options, monitor treatment response including the development of treatment-resistance as well as predict treatment response including potential adverse effects (such as toxicity). Liquid biopsies also offer an opportunity to detect diseases at an early stage and monitor recurrence particularly in cases, such as diseases of the central nervous system, where tissue biopsy is difficult. Some would argue the race to deliver the benefits of liquid biopsy that is currently largely based on genomic approaches risks ignoring the potential contribution of proteomics that could be of greater value and utility. The workshop will discuss the principles, process and practice of liquid biopsy in general and the role of proteomics in particular. Attendees will learn about both existing and emerging technologies that can be used for the pursuit of new liquid biopsy based tests and through interactive discussion will explore the challenges of delivering such protein based liquid biopsies to clinical use..

Welcome – State-of-the-Science in Liquid Biopsy

Session 1 – Biology, Technology and Discovery of Proteomic Liquid Biopsy Approaches
Session 2 – Translation of Liquid Biopsy To Clinical Use

Interactive Discussions

1. Bio-specimen selection, procurement and processing
2. Circulating proteins, exosomes, micro-vesicles and bio-specimen processing
3. Proteomic biomarker discovery strategies
4. Challenges and opportunities in translating liquid biopsy into ‘clinical laboratories’


Session 3 – Public-Private Partnerships: Collaborations with Industry, Academia and Government Sectors
Session 4 – Implementation of Liquid Biopsy to Point-of-Use/Point-of-Care

Interactive Discussions

1. Opportunities in the pre-competitive space for industry, academia and government collaboration
2. Challenges and opportunities in taking proteomics-based liquid biopsy to point-of-use or point-of-care
3. Regulatory requirements in implementing liquid biopsy
4. Harmonization and validation of liquid biopsy approaches for clinical use
5. Integration of proteomic liquid biopsy data with other molecular and clinical data

Detailed programme to be released: 27th July